Tildrakizumab
Ilumya, Ilumetri (tildrakizumab) is an antibody pharmaceutical. Tildrakizumab was first approved as Ilumya on 2018-03-20. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. It is known to target interleukin-23 subunit alpha.
| Trade Name | Ilumetri |
|---|---|
| Common Name | Tildrakizumab |
| Indication | psoriasis |
| Drug Class | Monoclonal antibodies: humanized, interleukins as target |
